ATLASATLAS fair value
ATLAS has no fair value for this stock today.
AbCellera Biologics (ABCL)
AbCellera Biologics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$12.83▲ +6.21%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
47%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on AbCellera Biologics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On AbCellera Biologics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives AbCellera Biologics a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $11.21 and $14.26; in 9 out of 10, between $9.05 and $17.66. Estimated annual volatility is 71%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $4.5B
- 52-week high
- $15.02
- 52-week low
- $2.75
- Revenue (12 months)
- $66.2M
- Revenue growth (YoY)
- +160.6%
- Gross margin
- 0.0%
- Operating margin
- -270.5%
- Net margin
- -194.9%
- Return on equity
- -17.3%
- Free cash flow (12 months)
- $-46.4M
- Beta
- 1.32
What this means
ATLAS does not publish a fair value for ABCL right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ABCL has traded between $2.75 and $15.02. Today it is 14.6% below that high and 367% above its low.
On the business: revenue grew 160.6% year over year; net margin is 194.9%.
Its beta is 1.32: it tends to move more than the market, both up and down.
About the company
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines.
Want to see everything about AbCellera Biologics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does AbCellera Biologics do?
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines.
What is the chance ABCL goes up next month?
47%: close to a coin flip. In half of the simulated outcomes, ABCL ends the month between $11.21 and $14.26.
How big is AbCellera Biologics and what is its P/E ratio?
AbCellera Biologics's market capitalization is $4.5B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is ABCL?
ATLAS estimates annual volatility at 71%. In a typical month, half of the outcomes end between $11.21 and $14.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer